Mangoceuticals (Mangoceuticals) EV-to-EBIT : -1.15 (As of May. 27, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mangoceuticals EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Mangoceuticals's Enterprise Value is $10.39 Mil. Mangoceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.02 Mil. Therefore, Mangoceuticals's EV-to-EBIT for today is -1.15.

The historical rank and industry rank for Mangoceuticals's EV-to-EBIT or its related term are showing as below:

MGRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -18.72 Med: -1.33 Max: -0.31
Current: -1.15

During the past 3 years, the highest EV-to-EBIT of Mangoceuticals was -0.31. The lowest was -18.72. And the median was -1.33.

MGRX's EV-to-EBIT is ranked worse than
100% of 429 companies
in the Healthcare Providers & Services industry
Industry Median: 17.65 vs MGRX: -1.15

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Mangoceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $5.31 Mil. Mangoceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-9.02 Mil. Mangoceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -169.92%.

Mangoceuticals EV-to-EBIT Historical Data

The historical data trend for Mangoceuticals's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mangoceuticals EV-to-EBIT Chart

Mangoceuticals Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBIT

-0.58

Mangoceuticals Quarterly Data
	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial					-3.06	-4.27	-1.80	-0.58	-0.59

Competitive Comparison of Mangoceuticals's EV-to-EBIT

For the Health Information Services subindustry, Mangoceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Mangoceuticals's EV-to-EBIT Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Mangoceuticals's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Mangoceuticals's EV-to-EBIT falls into.

Mangoceuticals EV-to-EBIT Calculation

Mangoceuticals's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	10.391	/	-9.021
	=	-1.15

Mangoceuticals's current Enterprise Value is $10.39 Mil.
Mangoceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.02 Mil.

Mangoceuticals (NAS:MGRX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Mangoceuticals's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-9.021	/	5.30906955
	=	-169.92 %

Mangoceuticals's Enterprise Value for the quarter that ended in Mar. 2024 was $5.31 Mil.
Mangoceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.02 Mil.

Mangoceuticals EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Mangoceuticals's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Mangoceuticals (Mangoceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Mangoceuticals Inc (NAS:MGRX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

15110 N. Dallas Parkway, Suite 600, Dallas, TX, USA, 75248

Website

https://www.mangoceuticals.com

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The platform provide access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED product.

Executives

Amanda Elizabeth Hammer	officer: Chief Operating Officer	5128 GADSDEN AVENUE, KELLER TX 76244
Jacob D. Cohen	director, 10 percent owner, officer: CEO	2101 GLENDALE DRIVE, PLANO TX 75023
Tiger Cub Trust	10 percent owner	19 RYDDINGTON PL, DALLAS TX 75230
Kenny Myers	director	5101 ADDISON CIRCLE,, UNIT 401,, ADDISON TX 75001
Lorraine Pamela D'alessio	director	8200 WILSHIRE BLVD, BEVERLY HILLS, CALIFORNIA CA 90211
Eugene M Johnston	officer: CFO	PO BOX 669047, CHARLOTTE NC 28266
Jonathan Arango	director, officer: President, COO and Secretary	15110 DALLAS PARKWAY, SUITE 600, DALLAS TX 75248
Alex P. Hamilton	director	26 LOOP ROAD, BEDFORD NY 10506